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Laboratory, North Melbourne, Victoria, AustraliaRecent advances in molecular biology have led to the develop- of side effects, the frequency of oral administration, but also the
ment of novel small molecules that target speciﬁc viral proteins
of the hepatitis C virus (HCV) life cycle. These drugs, collectively
termed directly acting antivirals (DAA) against HCV, include a
range of non-structural (NS) 3/NS4A protease, NS5B polymerase,
and NS5A inhibitors at various stages of clinical development.
The rapid replication rate of HCV, along with the low ﬁdelity of
its polymerase, gives rise to generations of mutations throughout
the viral genome resulting in remarkable sequence variation in
the HCV population, known as a quasispecies. The efﬁcacy of
DAAs is limited by the presence of those mutations that give rise
to amino-acid substitutions within the targeted protein, and that
affect the viral sensitivity to these compounds. Thus, due to the
high genetic variability of HCV, variants with reduced susceptibil-
ity to DAA can occur naturally even before treatment begins, but
usually at low levels. Not surprisingly then, these changes are
selected in patients either breaking through or not responding
to potent DAA treatment. In vitro or in vivo, six major position
mutations in the NS3 HCV protease (36, 54, 155, 156, 168, and
170) have now been reported associated with different levels of
resistance. The amino acid composition at several of the drug
resistance sites can vary between the HCV genotypes/subtypes,
resulting in different consensus amino acids leading to a reduc-
tion in replicative ﬁtness as well as reduced DAA sensitivity. Dif-
ferent amino acid diversity proﬁles for HCV genotypes/subtypes
suggest differences in the position/type of immune escape and
drug resistance mutations. Also, different pathways of resistance
proﬁles based on the chemical scaffold (linear or macrocyclic) of
the protease inhibitors have been described. This review ﬁrst
describes how resistance to a protease inhibitor can develop
and then provides an overview of the mechanism of how partic-
ular mutations confer varying levels of resistance to protease
inhibitor, which have been identiﬁed and characterized using
both genotypic and phenotypic tools. Future potential therapeu-
tic strategies to assist patients who do develop resistance to pro-
tease inhibitors are also outlined. The challenge developing new
HCV protease inhibitors should take into consideration not only
the antiviral potency of the drugs, the occurrence and importanceJournal of Hepatology 20
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Increasing the sustained virological response (SVR) in patients
with chronic hepatitis C (CHC) is becoming a reality with the
preclinical and clinical development of more than 50 new spe-
ciﬁc drugs active against HCV [1–3]. These drugs, collectively
named directly acting antivirals (DAAs), are under advanced
clinical trials to be used either as an adjunct to current
standard of care (SOC) therapy in triple, quadruple, or multiple
combinations of HCV antiviral therapies or in various
combinations of DAAs [4–10]. The encouraging data from early
clinical trials of HCV-speciﬁc protease and polymerase
inhibitors have been tempered by subsequent studies demon-
strating the early selection of resistant variants [11,12]. Drug
resistance can be an inevitable outcome using antiviral agents
because of the high adaptability of the hepatitis C virus
(HCV) and the failure to maintain a high pressure of inhibition
[13–17]. Not surprisingly, resistance has been demonstrated for
all classes of DAAs in more advanced clinical testing for NS3/4A
protease inhibitors and in vitro for nucleoside NS5B polymerase
inhibitors as well as the non-nucleoside NS5B polymerase
inhibitors [16,18]. Genotypic sequence analysis of HCV RNA
supports the concept that these early variants are pre-existing
species, present before initiation of therapy due to the high
genome replication rates and high intrinsic RNA polymerase
error rates, rather than being selected for de novo [19–24]. For-
tunately, analysis of these variants in replicon assays has sug-
gested that the substitutions associated with the greatest
resistance are also associated with reduced viral ﬁtness
[16,17,25,26].
The ﬁrst generation of protease inhibitors (telaprevir and
boceprevir) are in the ﬁnal stages of clinical development and it
is now important to better understand mechanisms of cross-
resistance (when a mutation that mediates resistance to one drug
also confers resistance to another in the same class) [4,27,28].
The second generation of protease inhibitors (PI) should result
in compounds with more powerful antiviral activity but unfortu-
nately, with still some level of cross resistance mutations within
the class [29–40]. The incidence and prevalence of resistance in
the different clinical trials should focus on the future use of the11 vol. 55 j 192–206
JOURNAL OF HEPATOLOGY
PIs and the role of potential combination therapies. Patterns of
resistance with PIs are described in this review and it is
essential that clinical practice guidelines be developed in order
to optimize and interpret resistance algorithms so that DAA ther-
apy can be tailored accordingly. Characterizing resistance to DAA
in clinical trials is essential for understanding how to optimize
the use of a drug regimen and to provide insights into strategies
aimed at maximizing SVR rates and thereby minimizing
resistance.Causes of antiviral drug resistance in the context of chronic
hepatitis C
Antiviral drug resistance reﬂects reduced susceptibility of a virus
to the inhibitory effect of a drug and results from a process of
adaptive mutations under DAA therapy. A resistance mutation
(nucleotide change) or substitution (amino acid change) is a
change observed for an emerging variant which signiﬁcantly
increases in proportion, on a population basis, during DAA admin-
istration. The risk of selection of drug resistance is related to the
incomplete suppression of viral replication. Several factors affect
this phenomenon including: high replication rates, low ﬁdelity
of the viral polymerase, selective pressure of the drug, role of rep-
lication space (liver turnover), ﬁtness of the escape variant and
genetic barrier of the drug.Dynamics of HCV variants: magnitude and rate of virus replication
plus ﬁdelity of the viral RNA polymerase
Because of the high mutation rate of the HCV polymerase (103
to 105) misincorporations per nucleotide copied and the high
viral production rates in vivo (approximately 1012 viruses per
patient per day [41]), it can be assumed that HCV exists as a
diverse population of non identical but closely related viral gen-
omes referred to as a quasispecies [42,43]. A viral quasispecies is
characterized by a dominant nucleotide sequence, or master
sequence, and a surrounding mutant spectrum, which can harbor
minority subpopulations [44].
The detailed study of the dynamics of viral variants present in
a quasispecies population has long been hampered by the lack of
sensitive sequencing methods. The recent development of deep
sequencing technologies may facilitate a better understanding
of the genetic composition and natural evolution of viral quasi-
species in the presence of antiviral drugs [45].
The diversity of the viral variants present in an infected indi-
vidual facilitates the adaptation of the quasispecies to external
pressure, such as antiviral treatment, thereby improving the
survival chances of the population. The speed of such adapta-
tion depends mainly on the turnover of the viral nucleic acid
acting as a source of new viral genomes [45]. Perelson and col-
leagues demonstrated by calculating the rates of generation of
various HCV variants, that the preexistence and selection of
drug-resistant variants is inevitable, and estimated the number
of substitutions a combination of direct antivirals would need
to achieve in order to adequately control HCV replication [17].
Thus, prior to antiviral therapy, because of this quasispecies
pool, variants carrying single and double mutations potentially
associated with DAA resistance will pre-exist, while three or
four mutations should present sufﬁcient genetic barrier
[16,17,25,26].Journal of Hepatology 201Selective pressure of the drug
The probability of a mutation associated with drug resistance
being selected out during therapy depends on the efﬁcacy of that
drug and this probability has been depicted graphically as a bell-
shaped curve [46]. Hence, a drug with low antiviral activity does
not exert signiﬁcant selection pressure on the virus and the risk
of drug resistance emerging is not high. Conversely, complete
suppression of viral replication allows almost no opportunity
for resistance to emerge because as highlighted above, mutagen-
esis is replication dependent [47]. Unfortunately, since mono-
therapies exert varying degrees of antiviral activity directed at
one single target site, they result in the highest probability of
selecting for drug resistance [11,48]. The ideal treatment regimen
exerts antiviral activity targeted at different sites in the viral life
cycle to reduce the risk of signiﬁcantly selecting drug-resistant
quasispecies. Not surprisingly, resistance emerges when replica-
tion occurs in the presence of drug-selection pressure. Another
known factor of emerging drug resistance variant is the poor
compliance of patients which should be taken into consideration.
Especially, since there will be triple therapy with the protease
inhibitor (three times a day), ribavirin (two times a day) and
pegylated interferon (once a week).
Amount of replication space in the liver
Replication space for a virus can be described as the potential of
the liver (hepatocytes) to accommodate new transcriptional tem-
plates for that virus. This then indicates that the eventual take-
over by an emerging escape variant is dependent upon the loss
of the original wild-type virus. This would be governed by factors
such as replication ﬁtness as well as the turnover, the number of
infected hepatocytes and proliferation of hepatocytes. Hepato-
cyte turnover in the normal liver is slow, displaying a typical
half-life of over 100 days [49], but this can be reduced to less than
10 days in the setting of increased necroinﬂammatory activity or
associated toxicity [49]. Thus, in a fully infected liver, synthesis of
new HCV transcriptional templates could only occur if uninfected
cells are generated by normal growth within the liver (from
hepatocyte proliferation and turnover) or there is loss of wild-
type dominant viral replication transcriptional templates from
the existing HCV-infected hepatocytes [16].
Replication ﬁtness of the drug resistant virus
Replication ﬁtness has been deﬁned as the ability to produce off-
spring in the setting of natural selection [47]. This is not a yield
measurement of viral replication and is usually measured in
in vitro coinfection competition assays. Several of these assays
have been developed for HCV. Although not a measure of resis-
tance per se, the viral ﬁtness (replicative capacity) of resistant
variants is an important factor, with implications for the emer-
gence of resistance. Viral ﬁtness can also be deﬁned as the repli-
cation efﬁciency of resistant variants, in a ratio to the replication
efﬁciency of wild-type (WT) HCV. Because the most commonly
available infectious virus system is based on a genotype 2a virus
(many new HCV drugs target genotype 1), the replication capac-
ity of HCV variants is typically assessed in vitro using a transient
replicon system, or can be examined by comparing colony forma-
tion efﬁciency of the mutant replicon RNA with that of WT vari-
ants in co-culture growth competition assays [50]. Moreover
replicon-based assays might underestimate the loss of ﬁtness1 vol. 55 j 192–206 193
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caused by PI-resistance mutations, because some mutations in
the NS3 protease domain speciﬁcally impair late steps in the viral
life cycle that involve intracellular assembly of infectious virus.
Protease inhibitor-resistant HCV mutants have been recently
shown to have reduced ﬁtness as a consequence of impaired pro-
duction of infectious virions [51]. Additionally, ﬁtness has been
determined in vivo by using HCV RNA levels and clonal sequenc-
ing to calculate the frequency of a given variant over time after
the end of dosing to assess the growth rate compared with WT
in the absence of drug-selection pressure [25]. The kinetics of
selection of different resistant variants suggests that these vari-
ants are present before dosing at different levels, depending on
their ﬁtness compared with WT [45]. A detailed examination of
intra-individual variation using cloning techniques or next gener-
ation sequencing approaches such as ultradeep pyro-sequencing,
may provide additional information regarding the evolution and
importance of low-level drug resistance variants and allow the
identiﬁcation of clinically relevant new variants [52,53].
Genetic barrier
The genetic barrier is the threshold probability that the virus will
mutate and escape from the selective action of the drug. It can
also be deﬁned as the number of mutations needed for the devel-
opment of primary antiviral drug resistance.
As the number of mutations required for resistance increases,
the genetic barrier increases [54]. Thus, the genetic barrier can be
viewed as the number of mutations required for a virus to become
drug resistant and the probability to selectmutation(s) in the pres-
ence of the drug. Fig. 1 illustrates how the rapid appearance of HCV
drug resistance results in treatment failure using monotherapyHigh
Low
Nucleos(t)ide
analog
inhibitors
Non-nucleos(t)ide
analog
inhibitors
1st generation
protease 
inhibitors
Fig. 1. Genetic barriers (low to high) for HCV Direct Antiviral Agents. The genetic ba
from the selective action of the drug. It can also be deﬁned as the number of mutations req
ﬁtness, can emerge quickly in contrast to Intermediate or High barrier: one mutation = h
194 Journal of Hepatology 201with a PI or a non-nucleoside polymerase inhibitor. Schematically,
a lowgenetic barrier is onewhich involves a primarymutation that
comes at a lowcost to the virus (in terms of ﬁtness) and can emerge
quickly. In contrast, a higher genetic barrier is one which involves
notonlyaprimarymutationwithahighcost toﬁtness, butalso sec-
ond or third mutation(s) in order to generate ‘‘complete’’ resis-
tance. Furthermore, second or third site mutations may also be
required in order to restore ﬁtness of these low-ﬁtness/high resis-
tance variants. In the case of the PIs, the genetic barrier is inﬂu-
enced by the HCV subtype 1a and 1b as well. Two nucleotide
changes are required to generate an aminoacid change in position
155 in subtype 1b isolates [12,55]: R155K [CGG? AAG], while
only one (R155K [AGG? AAG]) is needed for subtype 1a.
In contrast with the rapid emergence of drug-resistant vari-
ants to the PIs and non-nucleoside polymerase inhibitors, there
is no evidence of drug resistance emerging to the current nucle-
oside analog polymerase inhibitors, even when they are used as
monotherapy. Lack of resistance to these nucleoside analog
inhibitors may be due to signiﬁcantly reduced replication capac-
ity of the resistant variants (S282T of NS-5B) or different binding
sites of nucleoside and non-nucleoside inhibitors [56]. Indeed,
the nucleoside analog polymerase inhibitors seem to have a
higher genetic barrier to resistance than either the PI or non-
nucleoside polymerase inhibitors at least in the replicon system,
highlighting the potential clinical importance of these nucleoside
analog polymerase inhibitors in future HCV therapies [35,55,57].
Other factors
Host factors affecting antiviral therapy include previous drug
experience, compliance, host genetic factors (e.g. inborn errorsrrier is deﬁned as the threshold probability that the virus will mutate and escape
uired for a virus to become drug resistant. Low barrier: one mutation = low cost to
igh cost to ﬁtness and may require second or third mutation(s) to increase ﬁtness.
1 vol. 55 j 192–206
Fig. 2. The active site of HCV NS3 protease is shallow and located on the
surface of the enzyme and shown in this diagram with an example of a
protease inhibitor TMC-435 (Crystal structure of wild-type HCV NS3-4A with
TMC-435 (PDB-ID: 3KEE)).
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of metabolism and strength of interferon system responses)
[58] and the ability to efﬁciently convert the DAA to its active
metabolite (if they are acting as a prodrug) via several intracel-
lular phosphorylations (for example, in the case of nucleoside
analogs and their reliance on intrahepatic salvage enzymes)
[59]. In addition, there are sequestered sites/sanctuaries of viral
replication that may not be accessible to the antiviral agent.
Host genetic factors have been recently associated with the
reponse to antiviral therapy: a single nucleotide polymor-
phisms (SNPs) near the interleukin (IL)-28B (IFN-lambda)
region was found associated with the treatment response
[58]. Although all of the identiﬁed variants lie in or near the
IL-28B gene, none of them has an obvious effect on the func-
tion of this gene [60].
Kinetics of resistant mutants and viral dynamics model
From the preceding discussion, it is now possible to consider a
resistance mutation as a mutation observed in a variant popu-
lation which increases in relative proportion to the original
WT during drug administration. A model prediction of the
mutant frequency and viral load decay proﬁles after drug
administration has recently been reported [16,45]. During tela-
previr dosing, the overall viral load initially declined as the WT
was inhibited and replication space available to variants
increased, allowing pre-existing variants with sufﬁcient on-dos-
ing ﬁtness to emerge. The increase in replication space and the
on-dosing ﬁtness of variants were the primary determinants of
HCV RNA rebound during telaprevir dosing, with negligible con-
tribution from mutations during treatment. The ﬁnding of vari-
ants prior to dosing and within a week on-treatment in other
studies does suggest that the variants contributing to virologic
rebound in this study were likely to pre-exist [11]. The pre-
existence of variants is supported by the modeling results;
had they not pre-existed, calculations based on the HCV muta-
tion rate, replication rate, and HCV RNA level at baseline would
indicate that rebound is delayed. A mathematical model of the
monitoring and characterization of the dynamics of sensitive
and resistant viral populations demonstrated a biphasic
decrease of both drug-sensitive and drug-resistant virions after
drug dosing [6,7]. The frequency of the resistant variant under-
goes a substantial increase within a few days following drug
administration, consistent with observations in clinical studies.
The high frequency of drug-resistant variants observed early
in therapy may simply be a consequence of a rapid and pro-
found decline of wild-type virus, unveiling preexisting HCV
variants [16]. Over a longer time interval, the tradeoff between
the reduced susceptibility to PIs and resistance-associated ﬁt-
ness loss will probably determine whether such HCV variants
can dominate the virus population. This balance is affected by
several inter-related factors as a change in the replicative envi-
ronment occurs.
Small-molecule inhibitors of viral enzymes
The development of DAA that block essential viral enzymes rep-
resents a rational and straightforward approach to developing
new anti-HCV agents [61]. Although all HCV enzymes are, in the-
ory, equally appropriate for therapeutic intervention, the NS3-4A
serine protease, the NS5B RNA polymerase and the NS5A protein
have emerged as the most promising of targets so far. A numberJournal of Hepatology 201of competitive inhibitors of the NS3 protease as well as nucleo-
side and non-nucleoside inhibitors of the NS5B polymerase and
NS5A inhibitors are being developed [62]. The efﬁcacy shown
by NS3 serine protease and the NS5B RNA-dependent RNA poly-
merase inhibitors in recent proof-of-concept clinical trials has
validated the effort spent in search of more clinical candidates
thereby renewing interest in this area.HCV NS3 protease
The NS3 protein is a multifunctional protein that harbors a serine
protease located in the N-terminal one-third (189aa) which is
involved in cis-cleavage of the NS3-NS4A site. The NS3 forms a
heterodimer with NS4A and results in the subsequent down-
stream cleavage of the NS4A/4B, NS4B/5A, and NS5A/B junctions
in the nonstructural region of the polyprotein. The C-terminal
two-thirds of NS3 exhibits NTPase/RNA helicase activity
(442aa). HCV NS3-4A serine protease is a member of the chymo-
trypsin serine protease family and is a heterodimeric protease,
comprising the amino-terminal domain of the NS3 protein and
the small NS4A cofactor. Its activity is essential for the generation
of components of the viral RNA replication complex. Analysis of
the X-ray crystal structure of the enzyme reveals a shallow cata-
lytic site located on the surface of the protein, which has made
development of inhibitors a formidable task (Fig. 2). Attempts
to discover leads by traditional approaches of screening com-
pound libraries have proved futile and, therefore, researchers
adopted a rational structure-based drug design approach. Analy-
sis of the X-ray structure of the NS3 protease revealed close prox-
imity of S1–S3 and S2–S4 pockets. A number of novel approaches
have been used to design preorganized, depeptidized macrocyclic
inhibitors linking the P2–P4 groups and P1–P3 residues.1 vol. 55 j 192–206 195
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More recently, HCV NS3-4A protein was recognized as a mul-
tifunctional enzyme taking part in host immune evasion [63].
NS3-4A proteolytic activity is directly incriminated in this
immune host evasion by blocking the activation of interferon reg-
ulatory factor 3 (IRF-3) via cleavage of TRIF and also CARDIF
[64,65]. Theoretically, a potent HCV NS3-4A PI would potentially
have an additive or even synergistic impact on controlling HCV
replication and reducing persistence. Thus, the HCV NS3-4A PIs
act at one of the middle steps of the HCV replication cycle
(HCV polyprotein processing), and also at an initial step during
the triggering of the host response to HCV infection. Therefore,
the NS3 represents a dual therapeutic target, the inhibition of
which should not only block viral replication but also restoreTable 1. Description of the protease inhibitors in clinical phase. In vitro Huh-7 repl
company, chemical scaffold and type of structure (linear or macrocyclic). Non available
196 Journal of Hepatology 201hepatocyte innate immune control of HCV replication. This ﬁnd-
ing may explain the exceptional antiviral activity found in vitro
and in vivo, with potent HCV NS3-4A PIs [66].Protease inhibitors
For the PI molecules currently in clinical trials, the chemical
scaffold of the different HCV PIs can be divided into two classes:
macrocyclic compounds (MK 7009, TMC435350, ITMN191,
BI12202, GS-9256, ABT 450, and BMS650032, BMS 791325)
and linear ketoamids (VX 950, SCH503034, SCH567312)
(Table 1). The antiviral activity of these PIs is mainly relevanticon wild-type HCV 1b average range of antiviral activity (nM), pharmaceutical
structure (NA). ⁄Putative structure.
1 vol. 55 j 192–206
V36A/M T54A V55A Q80R/K R155K/T/Q A156S A156V/T D168A/V/T/H V170A
Telaprevir
(linear) * * 
Boceprevir
(linear) * 
SCH900518
(linear)
BILN-2061
(macrocyclic)
ITMN191
(macrocyclic) * * 
MK7009
(macrocyclic) * 
TMC435350
(macrocyclic)
BI-201335
(linear)
MK5172
(macrocyclic)
GS-9256
(macrocyclic)
ABT 450
(macrocyclic)
BMS-791325
(macrocyclic)
Table 2. Amino acid positions within the NS3/4A protease associated with resistance mutations to different NS3 protease inhibitors and a cross-resistance table of
different NS3 protease inhibitors based on mutations selected in patients from clinical studies and/or from in vitro studies. Resistance mutations of NS3 protease
inhibitors with a P4-fold increase in EC50 are shown in gray (Resistant) and resistance mutations described 64-fold change in EC50; are shown in white (S = susceptible)
EC50 = 50% effective concentration (replicon HCV-1b).
⁄Mutations associated with resistance in vitro only.
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activity of these current PIs against genotype non-1 genotypes
(except for genotype 2), is not as effective [67]. A number of
compounds are in preclinical phases with broader activity
across the genotypes and with more favorable cross-resistance
proﬁling. This distinction has led to two different resistance pro-
ﬁles, with the R155 and D168 substitutions mainly found asso-
ciated with the macrocyclic compounds rather than the linear
compounds. Substitution at the A156, V36 and T54 are more
strongly associated with resistance from the linear compounds
rather than the macrocyclic compounds (Table 2). Other more
class-speciﬁc mutations are found due to the contact affecting
the P2–P3 link, inducing a strong steric hindrance with a mod-
iﬁcation of the P2 positioning which cannot be compensated by
all the PIs and thus constitute one of the major cross resistance
mutations (Fig. 3) [68].Molecular modeling of protease mutations with HCV protease
inhibitors
Cross resistance mutations between linear ketoamids and
macrocyclic PIs: A156T and R155K
A156T is one of the major class-speciﬁc mutations that to date
has been found to affect PIs; this is because of the contact affect-
ing the P2–P3 link, inducing a strong steric hindrance with a
modiﬁcation of the P2 positioning which cannot be compensated
with P4–S4 and P5–S5 interactions (Fig. 4) [68].Journal of Hepatology 201R155K is the other class-speciﬁc mutation. Molecular model-
ing of the complex with a linear ketoamid or a macrocyclic indi-
cate that the alkyl side chain of the arginine has several Van der
Walls (vdW) interactions and so the substitution by lysine at 155
has an effect on the P2-substituted quinoline moiety of macro-
cyclics and induces a buried salt bridge formed by R155-D168.
Therefore, mutations at either position 155 or 168 could severely
disrupt this salt bridge and affect its interaction with both mac-
rocyclic protease inhibitors resulting in resistance. In contrast,
linear-ketoamide inhibitors, like VX-950 and SCH-503034, do
not possess a large P2 moiety that can force the formation of a
buried R155-D168 salt bridge. Both R155 and D168 side chains
adopt solvent-exposed conformations with all ﬁve HCV PIs tested
(VX-950, SCH-503034, ITMN-191, MK-7009, and TMC-435350).
The linear-ketoamide inhibitors make only a few contacts with
R155 and D168 side chains, which is consistent with low-level
resistance for R155K mutations observed (Fig. 5).V36M and T54A
V36M and T54A substitutions, individually, confer low level
resistance to boceprevir and telaprevir (fold resistance (FR)
<10), but confer intermediate resistance to telaprevir if associated
together (V36M + T54A, FR = 20), and high resistance level if
associated with A156T or R155K (telaprevir, FR >62) [25,69].
Therefore, V36M and T54A increase in a synergistic way (poten-
tiate), the resistance effect associated with the mutation R155K
or A156T. The buried residues Val-36 and Thr-54 are located near
the protease catalytic domain of HCV NS3-4A but are not close to1 vol. 55 j 192–206 197
Fig. 3. Three-dimensional overview of HCV NS-3. Location of PI-resistant
mutations is shown. Both A156 and R155 are located in the active site. T54 and
V36 are close to but not inside the active site and do not make direct contact with
telaprevir.
Reviewwhere the PI boceprevir and telaprevir are located in their respec-
tive complexes with HCV NS3-NS4 protease (d >6 Å). The distance
between the ketoamide warhead of both PIs and V36M and T54A,
are, respectively, 11 Å and 8 Å. Thus, V36M and T54A are not in
direct contact with both PIs (Fig. 6). These mutations will dis-
criminate boceprevir and teleprevir through an indirect resis-
tance mechanism [68]. In the wild type complex, Val-36 has
van der Walls (vdW) contacts with the neighbor residue Phe-43
(d = 3.4 Å), which is in contact with Gln-41 (d = 3.7 Å), a residue
in direct contact with the P10 part of the keto-amide based PIs
(d = 3.4 Å). In the case of the mutation V36M, from a beta
branched (Val) to a linear amino acid (Met), the contacts between
residues V36M and Phe-43 are lost, bringing more ﬂexibility to
the Phe-43 side chain. Like a domino cascade, the V36M muta-
tion, through Phe-43, will destabilize Gln-41 side chain decreas-
ing its hydrogen bonding with the P10 of boceprevir or telaprevir.
It is noteworthy that the mechanism of HCV NS3-4A protease
inhibition by keto-amide based PIs occurs in two successive
steps. First, a weak afﬁnity with no covalent complex occurs
which is then followed by the formation of a reversible covalent
complex of high afﬁnity. The Gln-41 side chain forms a hydrogenFig. 4. (A) VX 950 and (B) TMN-191 compounds resistance mechanism/A156T. A156T
the P2–P3 link, inducing a strong steric hindrance with a modiﬁcation of the P2 positio
198 Journal of Hepatology 201bond with the carboxamide of P10 moiety of boceprevir and tela-
previr in the reversible covalent complexes, and Gln-41 takes
part equally to the positioning of the P10 moiety during the no
covalent recognition step. The domino cascade events brought
by V36M substitution disrupts the hydrogen bond between
Gln-41 and P10 during the non-covalent recognition step and also
during the reversible covalent step.
In the wild type boceprevir cocrystal structure, T54 forms one
hydrogen bond with L44 (AOH  O@C, d = 2.8 Å, PDB-ID: 2OC8),
the neighbor residue of Phe-43 and also has a Van der Waals
(vdW) contact with the Phe-43 side chain [70]. Analyzing the
hydrogen bond network surrounding Thr-54, the Leu-44 forms
equally a hydrogen bond with the main chain of the catalytic res-
idue Ser-139 (NAH  O@C, d = 2.9 Å). Ser-139 is a crucial residue
for the proteolytic activity of NS3-4A protease (catalytic residue),
but Ser-139 is also crucial for the formation of the reversible
covalent complex with keto-amide based PIs like boceprevir
and telaprevir. Moreover, Thr-54 forms a weak contact with the
backbone of Ser-139 (d = 4.6 Å). T54A/S substitutions have been
described as boceprevir and telaprevir resistance changes, indi-
cating a probable molecular mechanism of resistance of T54A/S
strains for boceprevir and telaprevir [25,71]. If just the weak con-
tact between Thr-54 side chain and Ser-139 main chain was
incriminated in the resistance, the mutation T54S may bring
few perturbations because this substitution may allow Ser-54
to keep a weak contact with Ser-139. But the T54S change can
remove or decrease the direct contact with Leu-44 main chain
(hydrogen bond between Thr-54 side chain and Leu-44 main
chain). Thereby, the mutation T54S may have more impact on
Leu-44 compared to Ser-139. This mechanism would predict a
higher resistance of T54A strain to boceprevir and telaprevir
because of the elimination of electrostatic contacts with Ser-
139 and hydrogen bonding with Leu-44. This ﬁnding has been
validated by the phenotype analysis obtained by Susser et al.
showing an increase in resistance from T54S to T54A for both
telaprevir and boceprevir (from FR = T54S: 4, 5 to T54A: 10, 16,
respectively [25]. Phenotypic analysis has revealed that bocepre-
vir is more prone to resistance compared to teleprevir against the
T54A mutation (FR = 16 vs 10, respectively). Thr-42 may be the
explanation of this peculiarity. Indeed, the keto-amide P10 of
boceprevir contains a primary amide extremity allowing a doubleis one of more class-speciﬁc mutations that are found due to the contact affecting
ning which cannot be compensated with P4–S4 and P5–S5 interactions.
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Fig. 5. ITMN191 compound resistance mechanism/R155K (WT 5A) and mutant R155K (5B). Molecular modeling of the complex with a macrocyclic (example of ITMN-
191) indicates that the arginine has some Van der Walls (vdW) interactions with R155 alkyl side chain and that the substitution by the lysine in 155 on the P2 substituted
quinoline moiety of macrocyclic and induces a buried salt bridge formed by R155-D168. Therefore, mutations at either position 155 or 168 could severely disrupt this salt
bridge and affect its interaction with both macrocyclic protease inhibitors, resulting in resistance.
JOURNAL OF HEPATOLOGYhydrogen bonding with the S10 binding pocket. The ﬁrst hydrogen
bond occurs with Gln-41 side chain and the second with the main
chain (C@O) of Thr-42, while telaprevir contains a secondary
amide P10 extremity (N-methylcyclopropyl) which allows only
one hydrogen bonding with the Gln-41 side chain. Thereby, if
boceprevir undergoes a double hydrogen bonding perturbation
in the P1–S10 interactions domain, boceprevir will be more prone
to discrimation and resistance. This perturbation is communi-
cated from T54A through Leu-44 and Phe-43 to Thr-42. Like
V36M, the mutation T54A/S induces a domino cascade events
from residue 54 to the PI ketoamide warhead. T54A/S may per-
turb (T54S) or abrogate (T54A) electrostatic contact with Ser-
139 (perturbation of the reversible covalent complex) but equally
hydrogen bonding with Leu-44 and vdW contact with Phe-43.
This perturbation will drive through Phe-43, Thr-42 and Gln-41
to the destabilisation of the interactions occurring between S1
binding pocket and keto-amide P10 moiety. It is likely that the
T54S mutation, which introduces a cavity in the interior of the
protease, could affect the S139 position and conformation,Fig. 6. WT: crystal structure of wild type HCV NS3-4A with boceprevir (PDB-ID: 2OC
structure of V36M strain of HCV NS3-4A, PDB-ID: 2QV1). T54A: model of boceprevir bind
type crystal structure using GenMol software). Hydrogen bonds are depicted by green
depicted by double pink arrow and boceprevir in orange.
Journal of Hepatology 201thereby impacting the interaction of S139 with this class of inhib-
itor. On the other hand, the T54S mutation does not signiﬁcantly
affect macrocyclic inhibitors, since they do not rely on covalent
interactions with S139 [72].
D168A/V
The D168A/V changes are selected in vitro and in vivo and are
commonly associated with macrocyclic based PI dosing, like
TMC-435, ITMN-191, MK-7009 [71]. However, this macrocyclic
clustering is not the best unifying hypothesis, but instead may
be related to PIs containing a large P2, such as BILN-2061,
TMC-435, ITMN-191, MK-7009 (large P2 PIs) [72]. Molecular
modeling of BILN-2061 complexes [68] and structural analysis
of the co-crystal structure of NS3-4A protease complexed with
TMC-435 (as well as ITMN-191, PDB-ID 3M5L) has shown that
R155 adopts an extended conformation (TMC-435, PDB-ID:
3KEE) compared to the apo structure of NS3-4A protease or
co-crystal structures with PIs having small P2, like boceprevir8). V36M: model of boceprevir in complex with V36M HCV NS3-4A (from crystal
ing to HCV NS3-4A T54A strain (obtained by mutation of Thr-54 to Ala from wild
dashed, van der Walls contact by beige double dashed arrow, lost of contact are
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Fig. 7. WT: crystal structure of wild type HCV NS3-4A with TMC-435 (PDB-ID: 3KEE). D168A: model of TMC-435 binding to HCV NS3-4A D168A strain (obtained by
mutation of Asp-168 to Ala from wild type crystal structure 3KEE using GenMol software). Hydrogen bonds are depicted by green dashes, salt bridge by yellow dashes, loss
of contact (salt bridges) are depicted by double pink arrow and TMC-435 are depicted in orange.
Review(PDB-ID: 2OC8) as well as boceprevir analogs (PDB-ID: 2OBO,
2OCO) and telaprevir analogs (PDB-ID: 2P59), pdb-ID: 3KEE)
[73] (Fig. 7). This extended R155 conformation optimizes vdW
contacts between P2 and S2 and more importantly allows elec-
tronic p-stacking interactions between P2 subunit and S2 bind-
ing pocket. In both types of structures (large and small P2 PIs)
D168 forms strong salt bridges with R123 from S4 binding
pocket and R155 from S2 binding pocket. Therefore, D168 links
S2 to S4 binding pocket through strong salt bridges (Fig. 2). For
large P2 PIs like TMC-435 or ITMN-191, D168 ﬁxes the guanid-
inium extremity system of R155 (taking part of S2) toward the
P2 aromatic moiety of PI: indoline like for BILN-2061, TMC-435,
or isoindoline like for ITMN-191 and MK-7009. The substitu-
tions D168A/V replace the acidic negatively charged residue
Asp to an apolar and hydrophobic residue Ala or Val and abro-
gate the key structural salt bridges between residue 155 and
168. Losing this structural anchoring, R155 will gain more ﬂex-
ibility and conformational freedom, decreasing its interactions
with the large P2 of PI. This mechanism is in agreement with
the resistance proﬁles of TMC-435, ITMN-191, and MK-7009
showing in vivo the selection of D168 mutations (mainly
D168A/V), and also during the selection of BILN-2061 drug
resistance in vitro.HCV drug monitoring resistance tools
Information on patterns of resistance to- and cross-resistance
between antiviral agents is increasingly available and may be
important for decisions on how to combine drugs to achieve an
optimum antiviral effect. Two complementary methods are used
to characterize viral resistance: genotypic and phenotypic assays.
Data from the clinical trials carried out so far, have indicated that
sensitive methods should be adopted in order to assess HCV drug
resistance. The use of genotypic-resistance analysis to assist
therapeutic decision-making in patients using PCR-sequencing,
which is the reference method, provide insight into strategies
aimed at maximizing SVR rates and thereby minimizing resis-200 Journal of Hepatology 201tance. However, there are no commercial assays available yet to
characterize DAA resistance that can be used in routine clinical
practice.
Genotypic (sequence analysis) assays
Genotypic analysis of HCV enables the identiﬁcation of individ-
ual and combinations of nucleotide substitutions that are
known to confer resistance to speciﬁc antiviral agents. Initial
characterization of the resistance proﬁle for a drug requires
comparing viral sequences before, during, and after treatment
to detect changes from baseline (pre-treatment) that could
occur with a particular drug treatment; this could help to
‘‘individualize’’ drug combinations in order to attain maximum
virus suppression thereby avoiding treatment failure [12]. A
general understanding of fundamental assay technology, proto-
col feasibility, data interpretation, and sources of data variation
all play a role in the selection of the optimal genotyping assay
for the clinical microbiology/virology laboratory. Identiﬁcation
of the limitations of each assay is important for the clinician
to appropriately interpret and apply test results to patient care
(Table 3). The detection of viral resistance depends on the sen-
sitivity of the assay [5]. For example, although population-
based PCR sequencing methods are relatively simple to conduct
and most frequently used, they cannot determine linkage
between different mutations in a single variant, or detects vari-
ants with mutations that are present in less than 15–25% of
the population [52]. The level of resistant variants present
before treatment is initiated will most likely be below this
limit of detection and can only be determined using ultrasensi-
tive methods including clonal sequencing, ultra-deep sequenc-
ing or the TaqMan mismatch ampliﬁcation mutation assay
(TaqMAAMA). This latter assay can detect and quantify known
minor resistant variants of HCV and has been shown to corre-
late well with clonal sequencing results. TaqMAMA was linear
over a wide range of mutant levels (0.01–100%), and could
detect consistently variants at 0.1% level [53]. The assay
was highly reproducible, with a coefﬁcient of variance of
approximately 10–30%. However, the assay also has limitations1 vol. 55 j 192–206
Table 3. Diagnostic tools used for minor variants determination: description, principle, advantage, and drawback.
Principle  
Sensitivity
Advantages
Drawbacks 
Clonal
sequencing
Molecular cloning   
Sequencing of numerous clones
)senolc001:%1(%01>
0.1%:1000 clones
dohtemecnerefeR
All mutations detected
Double mutant detected
Errors/recombination during PCR
Bad sensitivity  
Bad NPV
Nb of clones and sequences ++
Costly and hard time labour
Lack of automatisation
Single genome
sequencing 
Limits dilution (1 single genome)
Numerous PCR  and sequence
%2
All mutations detected 
Double mutant detected
1 single copy of DNA?
Costly and hard time labour
Lack of automatisation
Allele
specific 
PCR
Mismatch amplification 
mutation assay
%2.0-30.0
Sensibility +++
Easy to perform
Possible quantitation
tsocwoL
Known position of resistance
Limited number of mutations
detceted
Bad specificity 
Neighbour polymorphisms
few standardisation
Ultradeep
sequencing
Multiples short 
sequences analyzed
 200 to 400 nt 
0.05-1%  
Sensibility ++
Automatisation 
Quantitation
Short sequences 
CV >104 copies/ml
Availability
Equipment/cost ++
Interpretation
JOURNAL OF HEPATOLOGYrelated to the fact that HCV exists in patients as a quasispecies
swarm which may result in signiﬁcant sequence polymorphism
near the mutation site [53]. DNA chip technologies and
sequencing with microchip based technology using oligonu-
cleotide microarrays is still in development for HCV genotyp-
ing. Additionally, given the variability of HCV and the
possibility that HCV populations may evolve rapidly, not all
substitutions observed on treatment should be considered
drug-selected changes. Appropriate statistical tests for a partic-
ular set of sequence data plus an expert virological opinion
should be employed to identify signiﬁcant drug-selected substi-
tutions as per the HIV-drug resistance interpretations [74]. The
cost beneﬁt of these assays in the context of the overall cost of
the PIs, will need to be determined.HCV phenotypic assays
Phenotypic assays assess the degree of decreased susceptibility
conferred by a substitution(s) by measuring the EC50 (the
effective concentration of drug required to inhibit replication
by 50%) in an enzyme or replicon based assay of HCV variants
for drug susceptibility in vitro. The fold change in sensitivity
can be calculated as the EC50 value of the isolate/EC50 value
of the reference strain (e.g. WT). At present, these assays can-
not be used in clinical studies to monitor the drug resistance
proﬁles due to intense labor demands, cost and time. More-
over, standard replicon assays limit the assessment of the
inhibitory activities of anti-HCV compounds to a few labora-
tory-optimized strains and may not reﬂect the range of activi-
ties of a compound against the heterogeneous viral population
that exists in the diverse HCV-infected community of patients
[28,48,71,75,76]. Biological and/or clinical cut-offs will be nec-
essary to interpret the clinical signiﬁcance of these shifts in
phenotypic fold change.Journal of Hepatology 201Patterns and pathways of resistance
In clinical trials with telaprevir and boceprevir, resistance associ-
ated mutations have emerged quickly (less than 15 days) in
patients on monotherapy. This strongly suggests the pre-exis-
tence of quasispecies harboring drug resistance mutations at
low frequencies, given their rapid appearance after commence-
ment of drug therapy. The incidence of resistance inversely corre-
lated to SVR which is related to the potency of the antiviral
activity: the compound with the highest antiviral activity (EC50
in replicon 1–50 nM) resulted in the strongest suppression of
viral replication. As highlighted above, the ﬁrst generation of Lin-
ear Ketoamids (telaprevir and boceprevir) select quite similar
resistance proﬁles with the V36 and T54 mutations whereas mac-
rocyclic inhibitors exhibit a common pathway with D168 substi-
tutions. The R155K and A156 T/S substitutions are cross-resistant
for all the Pis [12,16,48].
Telaprevir
Variants resistant to telaprevir were identiﬁed and characterized
early in vitro [12,16,48]. The replicon system, based on a genotype
1b isolate showed an increase in mutations in position 156 of the
NS3 protease domain with the substitution of alanine to serine
(A156S), valine (A156V), or threonine (A156T). Using a highly
sensitive sequencing assay that detects minor populations of viral
variants (>5%), mutations were identiﬁed that conferred low-
level (V36M/A, T54A, or R155K/T) or high-level (A156V/T and
V36/R155) resistance to telaprevir in vitro. In patients who had
a viral rebound on telaprevir alone, the R155K/T and A156V/T
variants were detected during the initial steep decline in HCV
RNA. During the rebound phase, the R155K/T and A156V/T vari-
ants were replaced by V36 (M/A)/R155 (K/T) double mutant vari-
ants. As discussed above, single substitutions in R155 are
described for genotype 1a (AGG? AAG), whereas in genotype1 vol. 55 j 192–206 201
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1b the variant R155T requires a double nucleotide mutation
(CGG = R arginine to CCG = proline, then to ACG = threonine,
probably by a telaprevir-sensitive intermediate with proline in
position 155) [52]. Also the V36A variant has been only described
in genotype 1a in vivo for similar reasons [12,16,48]. Two other
second site substitutions have been observed in vitro: Q41R and
F43S, with a lower impact on fold resistance.
In the PROVE 2 trial, breakthrough was found in 8.67% of
patients and relapse in 23.94%, and low level-resistance mutants
were present in 10 out of 22 patients with breakthrough and 35
out of 42 patients with relapse [77]. The interim analysis of the
EXTEND Phase III (long-term follow-up of patients with chronic
hepatitis C treated with telaprevir in combination with Peginter-
feron Alfa-2a and ribavirin) study enrolled 56 patients who failed
to achieve SVR from PROVE1 (N = 30), PROVE2 (N = 42), PROVE3
(N = 99) and Study 107 (N = 31), a SVR was durable in 99%) in a
median time to follow-up: 22 months after SVR (range 5–35).
The main mutations observed in this study were the same as
those observed in PROVE 1 and PROVE 2: namely 36, 54, 155,
and 156. Interestingly, 85% of genotype 1a patients with detect-
able resistant variants were infected with HCV V36M + R155K.
Moreover, 89% of non-SVR patients (50 out of 56) who had viral
variants with reduced telaprevir susceptibility at the end of the
earlier studies no longer showed evidence of resistance by the
end of follow-up and the resistant variants were replaced by
WT virus (median follow-up time: 25 months from end of prior
study [78].
Boceprevir
In vitro studies revealed that T54A, A156S/T, V170A are associ-
ated with different levels of resistance [11]. Phase II and III clin-
ical studies (Sprint 1 and Sprint 2) indicated that A156S/T and
V36M are the most frequent substitutions observed. Substitu-
tions of >25% of the populations were: V36M, T54S, and R155K,
while the less common (5 to 25%) were T54A, V55A, R155Y,
A156S, V158I, V170A, and the infrequent changes (<5%) included:
V36A, V36L, and I170T [11]. In the boceprevir studies, a lead in
phase combining pegylated interferon and ribavirin during the
ﬁrst 4 weeks and then the triple therapy was utilized, which
may in theory decrease the viral load thus decreasing the risk
of viral resistance. Interestingly, the mean frequency of viral vari-
ants was 14% at the end of treatment. Results from a 3 year long
term follow-up of 604 patients receiving boceprevir in naive
patients (SPRINT-1) and non responders (P03659, P04887) indi-Table 4. Classiﬁcation of outcomes of treatment for chronic HCV infection.
RVR Undetectable HCV RNA at week 4 of 
Undetectable HCV RNA at week 12 o
Undetectable HCV RNA at weeks 12 
cEVR (complete EVR)
eRVR (extended EVR)
SVR Undetectable HCV RNA at the end of
lacigoloriV
hguorhtkaerb
HCV RNA levels initially decrease (even t
on treatment (usually 1- 2 log10), but s
Non-response  
Null response
Partial response  
HCV RNA levels decrease slowly and to 
<1 log10 decrease in HCV RNA levels
 ≥2 log10 decrease in HCV RNA levels
Relapse Undetectable HCV RNA levels at com
202 Journal of Hepatology 201cated that SVR persists for at least 2 years after the end of treat-
ment in the 290 responder patients. Among the 174 patients with
boceprevir associated resistance substitutions detected, 64% were
R155K, 32% were T54S and 33% were V36M, with a variable time
of disappearance of mutations indirectly reﬂecting the loss of ﬁt-
ness of these viral variants [79].
The newly identiﬁed substitutions V158I–V163L have been
selected in vitro and are associated with telaprevir and bocepre-
vir-drug resistance [80]. V158I conferrs low level resistance (as
shown by a 2.5-fold increase in inhibition constant Ki to bocepre-
vir but not to telaprevir. Structural analysis of the NS3 protease
active site showed that V158 is part of the substrate binding
pocket and is in direct contact with the terbutyl P3 of boceprevir.
Another new variant V55A, is associated with resistance in
patients treated with boceprevir and telaprevir [25].
Difference in telaprevir and boceprevir treated patients for the
frequency of detection and/or resistance levels between the two
drugs have been observed, and this was mainly applicable for
the T54A and V170A mutations.Clinical aspects of resistance
Deﬁnitions of response
All patients receiving antiviral treatment therapy for CHC should
be closely monitored for virologic response and breakthrough
and for durability of response and viral relapse after treatment
has stopped. Table 4 summarizes the different treatment out-
comes and response for chronic HCV infection using frequent
monitoring of HCV RNA levels for prompt detection of treatment
failure and resistance.
How to best prevent resistance?
Prevention of resistance is a clinical challenge and can be
achieved by implementing and considering several factors: (1)
using a potent antiviral drug as demonstrated by its ability to
exhibit the lowest incidence and prevalence of drug resistant
mutants in the clinical trials done with the current generation
of protease inhibitors [25]; (2) reach high level of residual plasma
and tissue concentration by plasma drug monitoring. Preclinical
studies of boceprevir demonstrated the frequency of emergence
of resistant mutants in relation to the dosage of boceprevir, that
at the concentrations 6  EC90 and 12  EC90 the frequency of
resistant cells was 0.14 and 0.02%, respectively; (3) Maintain
good compliance of patients by implementation of programmestreatment
f treatment
and 24 of treatment
 treatment, and for at least 24 weeks after completion of treatment
o undetectable levels), followed by a clinical relevant increase while 
pecific conditions vary between clinical trials. 
different extents, but never become undetectable 
 by weeks 4 or <2 log10 decrease in HCV RNA levels by week 12 
 by week 12, but never undetectable 
pletion of treatment, but becoming detectable during follow-up
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promoting patient adherence to treatment and (4) by increasing
the genetic barriers to escape, typically by the use of combina-
tions of drugs. This latest point may also be consolidated by using
ribavirin in triple combination therapy, since the percentage of
breakthrough was less when comparing the arm without ribavi-
rin with both boceprevir and telaprevir [6,77].Cross resistance mutations
Cross-resistance occurs when resistance mutations are selected
that are common to more than one drug within each class. This
is typical for inhibitors that bind the same pocket but not neces-
sarily for inhibitors with the same mechanism of action (see
molecular mechanism section). Genotyping analyses show a lar-
gely overlapping cross-resistance proﬁle of boceprevir and
telaprevir. Two mutations, A156T and R155K are associated with
resistance to all the protease inhibitors. A156T, conferring high
level of resistance and associated with reduced virological ﬁtness,
is mainly selected in vitro but occurs to a lesser extent in vivo. The
R155K mutation confers low level of resistance to the linear com-
pounds but results in high level of resistance to the macrocyclic
group, and is frequently found in vivo. This change is costly for
the virus and results in a loss of ﬁtness. It is therefore not surpris-
ing that for these two substitutions, an inverse correlation
between resistance and ﬁtness has been found: the most resis-
tant variant had the lowest ﬁtness.Clinical impact of resistance to the PIs
Table 2 shows mutations that have been shown to confer resis-
tance to the PIs at varying levels, typically measured by the fold
change in EC50 from WT. For example, the R155K variant confers
low levels of resistance (<10-fold increase in EC50 compared with
the WT) to boceprevir and telaprevir in vitro, and higher levels of
resistance to BILN2061 (250 fold increase) and ITMN-191 (70-
fold increase) [20]. However, what is more relevant in the clinic
than a fold change is the protein-adjusted fold change and drug
exposure. Drug concentrations (Ctrough) in a patient need to
achieve levels that exceed the protein-adjusted EC50 value of
resistant variants in order to effectively control these variants
clinically. Therefore, clinical resistance will always be relative
to the level of resistance conferred by a variant and the drug
exposure in the patient. Characterizing the variants that arise
clinically can give further insight into the drug levels that may
be present in patients and the ability of the regimen to suppress
both WT and resistant variants.
Both groups of PIs (macrocyclic and linear) bind at the active
site of NS-3 and so there is some overlap in resistance proﬁles.
For example, the R155K mutation has been shown to confer resis-
tance to both linear and macrocyclic inhibitors in vitro, albeit at
different levels [18]. Based on the different structures of macro-
cyclic and linear inhibitors, the selection of variants with changes
at different sites outside of the active site may be expected. For
example, the D168 position has been shown to be important
for macrocyclic protease inhibitors, while positions V36 or M54
are important for the linear inhibitors.
Variants with decreased susceptibility to PIs are likely to pre-
exist at low levels since they are typically ﬁtness impaired and
thus are rarely detected by population sequencing. However, if
their ﬁtness approximates that of WT virus they can be presentJournal of Hepatology 201at higher levels and thus can be detected more frequently in
the untreated population. For example, a population sequence
analysis of the NS3/4A protease in 570 treatment-naïve patients
with chronic HCV infection revealed that variants that confer
resistance in varying levels of protease inhibitors occur naturally
at a very low frequency in the HCV-infected patient population
(<1% each) [20,22]. If a more sensitive assay is used, then it can
be revealed that two variants (T54A and V170A) with reduced
susceptibility to boceprevir were found to exist at low levels in
the viral population before boceprevir treatment was initiated
(in 1 or 2 clones per 90 clones sequenced) [23].
Although the clinical impact of pre-existing viral variants on
treatment outcome requires further study, their presence may
not necessarily predict treatment failure. One recent analysis
showed that even patients who had 100% V36M low-level tela-
previr-resistant variant at baseline achieved an SVR on a telapre-
vir-based treatment (3 out of 4 patients with V36M achieved an
SVR), suggesting that the presence of resistant variants may not
necessarily preclude successful treatment [20].Hepatitis C virus drug resistance and immune-driven
adaptations
Another issue for consideration in DAA resistance is related to the
overlapping selection pressures from HCV PIs and the host’s
immune response. Recent data have suggested that variation at
the drug resistance sites can occur in the absence of the speciﬁc
drug pressure, and other selection pressures such as the host’s
immune response may be occurring at these sites. Hence, among
individuals infected with subtype 1a, 21.5%, for 1b 44.4% and for
3a 41.8% exhibited genetic variation at a known drug resistance
site. Speciﬁc regions within the HCV protease (and polymerase)
are under both potential HLA-driven pressure and therapy selec-
tion and six HLA-associated polymorphisms have now been iden-
tiﬁed [81]. Furthermore, because very few individuals worldwide
have been exposed to DAA drugs, the drug resistance variations
identiﬁed here are unlikely to be attributable to the transmission
of resistant viruses from individuals previously exposed to these
drugs.The issue of ‘‘Archiving’’ of HCV drug-resistance substitutions
The question of the existence of compartments harboring HCV
drug resistant mutants against the DAAs, as has been observed
in HIV infection, requires consideration [82]. The basis for the long
term persistence of PI-resistant variants mutants at the end of
therapy and their potential source in different anatomic sites does
need to be explored in the future. The present notion is that this
reservoir does not decay because it is being continuously replen-
ished by a low level of ongoing viral replication [83]. As such this
reservoir will hamper the future use of other PI. The issue remains
unresolved and requires clariﬁcation as it will impact on a number
of treatment intensiﬁcation studies with other classes of DAAs.Genotype 1 subtype and HCV PI resistance
In vitro selection of drug resistance carried out in the replicon
model are limited by the use of only a single HCV subtype, GT-1 vol. 55 j 192–206 203
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1b, HCV subtypes can vary by up to 25% at the nucleotide level,
and this variability may lead to subtype speciﬁc differences in
the resistance proﬁles [55]. The previously reported replicon
resistance studies have been performed using GT-1b replicon
cells and did not address substitutions that emerged in GT-1a-
treated patients The double mutants V36M + R155K have been
identiﬁed only in GT-1a infected patients treated with telaprevir
and not in GT-1b infected patients [6,11,48,77]. The reasons for
this have already been discussed above.
In clinical studies of telaprevir alone or in combination with
pegylated interferon (with or without ribavirin), selection of
resistant variants and viral breakthrough have been observed
consistently more frequently in patients infected with HCV sub-
type 1a than subtype 1b. [11,48]. Several resistant variants were
selected typically in subtype 1a- (V36M, R155K/T) or 1b- (R155Q,
V170A) infected patients [11,48]. Additional results from SPRINT-
1 indicated that the most common resistance mutations in geno-
type 1a patients not achieving SVR was V36M, T54S, and R155K,
whereas mutations T54A, T54S, A156S, and V170A were identi-
ﬁed in genotype 1b patients [8]. Differences between subtype
1a- and 1b-infected patients also were observed for macrocyclic
NS3 protease inhibitors (ITMN191/R7227, BI201335) [48]. Taken
together, these data highlight the need to determine the subtypes
of genotype 1 in patients receiving DAAs treatment. Of note, due
to the lower power of discrimination of the 50 non coding region
to distinguish the subtype 1a from 1b, we strongly underline the
importance of the choice of another region as NS5b or E1 for HCV
genotyping [19,84].Combination therapies and SOC-free treatments
Data from the monotherapy with telaprevir for 15 days indi-
cated a rapid emergence of DAA resistant variants [11]. These
resistant variants can be eliminated with a combination drug
regimen by pegylated interferon plus ribavirin [20]. It is clear
that monotherapy with a DAA is not possible because resistance
mutants appear in a few days of treatment resulting in virolog-
ical rebound and treatment failure. In this scenario, researchers
are looking at using combinations of DAAs targeting different
viral functions for which there is no cross-resistance, as has
been successfully applied at preventing resistance in HIV treat-
ment. The rationale for an oral combination treatment for HCV
is based on the present HIV treatment HAART regimen, in which
multiple direct-acting antiviral drugs that target different steps
of viral replication are combined to increase the amount of viral
suppression (i.e. potency) and to prevent or delay the emer-
gence of antiviral resistance (i.e. genetic barrier). DAA-resistant
variants have been shown to be susceptible to peg-interferon
or ribavirin, in vitro [11] and in vivo [4]; moreover, the addition
of these agents has been shown to suppress the emergence of
variants. Using the combination of the nucleoside analog
RG7128 (high genetic barrier drug) with DAAs, such as the PIs
that have a lower barrier to resistance, will reduce the chance
of drug resistance emerging [73]. The INFORM-1 study conﬁrms
this beneﬁt in vivo as the combination of RG7128 and danopre-
vir prevented resistance-associated virological breakthrough
that has been reported with monotherapy with the PI. This
observation was conﬁrmed in SOC-free clinical trials combining
among other DAAs, BI-201335, boceprevir, ITMN-191, and tela-
previr [29–32,85–87].204 Journal of Hepatology 201Conclusions
The rapid appearance of HCV drug resistance suggests that treat-
ment failure with monotherapy using a PI may be inevitable. Data
from in vitro studies, early-stage clinical trials and mathematic
modeling suggest that tailoring combinations of direct antiviral
drugs shouldbebeneﬁcial topatientswithCHC.However, sensitive
methods to detect minor variants should be used before re-treat-
ment of patientswith the same class of antiviral drugs and the pos-
sibility of transmission of resistant viruses when these therapies
become more widely available will need further consideration in
the future. The resistance proﬁling does remain a challenge for
the next generation of protease inhibitors; thus, the lessons from
HIV infection treatment indicate that combinations of drugs with
different mechanisms of action will be an attractive strategy for
hepatitis C. The higher genetic barrier to resistancewith the nucle-
oside analog (RG7128) polymerase inhibitors compared with
either the protease or non-nucleoside polymerase inhibitors in
the replicon system [52], highlights the clinical importance of the
use of combinations of nucleoside analog polymerase inhibitors
and protease inhibitors in future HCV therapies.
Key Points  
The HCV NS3 Protease-inhibitor associated mutations 
occur quickly (less than 15 days) when monotherapy is 
used. Monotherapy will lead to selection of resistant 
variants that, in turn, could produce cross-resistance to 
the whole class of drugs due to overlapping resistance 
profiles. 
Combinations of Protease Inhibitors with other class of 
antivirals with separate modes of action & non-
overlapping resistance profile is preferable. 
The genetic barrier of the Protease Inhibitors is low, 
indicating that the number of mutations required for a 
virus to become resistant to a Protease Inhibitor is also 
low, and thus, the probability of selecting a mutation in 
the presence of the drug is high.  
There is long term persistence of HCV NS3 Protease-
inhibitor associated mutations after the end of therapy. 
Cross resistance mutations exist between the different 
protease inhibitors. 
Ribavirin prevents viral breakthrough in combination 
with Pegylated Interferon and protease inhibitors. 
Detection of resistance should be done using sensitive 
assays that detect quasispecies at the level of 5-10% 
of the overall population. 
Subtyping of genotype 1 will clarify the different types 
of resistant variants to the PIs. Conﬂict of interest
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